Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - peginterferon alfa-2a, quantity: 135 microgram - injection, solution - excipient ingredients: water for injections; sodium acetate; acetic acid; polysorbate 80; sodium chloride; benzyl alcohol - chronic hepatitis c (chc): the combination of pegasys and copegus is indicated for the treatment of chronic heptitis c in patients who have received no prior interferon therapy (treatment naive patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin. the combination of pegasys and copegus is also indicated for the treatment of chronic hepatitis c in patients with clinically stable human immunodeficiency virus (hiv) co-infection who have previously not received interferon therapy. pegasys monotherapy is indicated for the for the treatment of chronic heptitis c in treatment naive patients (see dosage and administration; chronic hepatitis c: treatment naive patients). patients must be 18 years of age or older and have compensated liver disease. chronic hepatitis b (chb): pegasys is indicated for the treatment of chronic heptitis b in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.

Canada - English - Health Canada

merck canada inc - interferon alfa-2b - solution - 6000000unit - interferon alfa-2b 6000000unit - interferons

Canada - English - Health Canada

merck canada inc - interferon alfa-2b - solution - 10000000unit - interferon alfa-2b 10000000unit - interferons

Canada - English - Health Canada

merck canada inc - interferon alfa-2b; water - kit - 18miu; 1ml - interferon alfa-2b 18miu; water 1ml - interferons

Canada - English - Health Canada

merck canada inc - interferon alfa-2b - liquid - 15000000unit - interferon alfa-2b 15000000unit - interferons

Canada - English - Health Canada

merck canada inc - interferon alfa-2b - liquid - 25000000unit - interferon alfa-2b 25000000unit - interferons

Canada - English - Health Canada

merck canada inc - interferon alfa-2b - liquid - 50000000unit - interferon alfa-2b 50000000unit - interferons

United States - English - NLM (National Library of Medicine)

pharmaessentia usa - ropeginterferon alfa-2b (unii: 981tme683s) (ropeginterferon alfa-2b - unii:981tme683s) - besremi is indicated for the treatment of adults with polycythemia vera. besremi is contraindicated in patients with: - existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt - hypersensitivity to interferons including interferon alfa-2b or any of the inactive ingredients of besremi - moderate (child-pugh b) or severe (child-pugh c) hepatic impairment - history or presence of active serious or untreated autoimmune disease - immunosuppressed transplant recipients risk summary available human data with besremi use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal studies assessing reproductive toxicity of besremi have not been conducted. based on mechanism of action and the role of interferon alfa in pregnancy and fetal development, besremi may cause fetal harm and should be assumed to have abortifacient potential when administered to a pregnant woman. there are adverse effects on maternal and fetal outcomes associated with polycythemia vera in pregnancy (see clinical considerations) . advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage is 2-4% and 15-20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk untreated polycythemia vera during pregnancy is associated with adverse maternal outcomes such as thrombosis and hemorrhage. adverse pregnancy outcomes associated with polycythemia vera include increased risk for miscarriage. there are no data on the presence of besremi in human or animal milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in breastfed children from besremi, advise women not to breastfeed during treatment and for 8 weeks after the final dose. besremi may cause embryo-fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . pregnancy testing pregnancy testing prior to besremi treatment is recommended for females of reproductive potential. contraception females advise female patients of reproductive potential to use effective contraception during treatment with besremi and for at least 8 weeks after the final dose. infertility females based on its mechanism of action, besremi can cause disruption of the menstrual cycle [see clinical pharmacology (12.1)] . no animal fertility studies have been conducted with besremi. safety and effectiveness in pediatric patients have not been established. clinical studies of besremi did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other therapy. no dose adjustment is necessary in patients with estimated glomerular filtration rate (egfr) ≥30 ml/min [see clinical pharmacology (12.3)]. avoid use of besremi in patients with egfr <30 ml/min [see warnings and precautions (5.12)]. besremi is contraindicated in patients with hepatic impairment (child-pugh b or c) [see contraindications (4)] . increased liver enzyme levels have been observed in patients treated with besremi. when the increase in liver enzyme levels is progressive and persistent, reduce the dose of besremi. if the increase in liver enzymes is progressive and clinically significant despite dose-reduction, or if there is evidence of hepatic impairment (child-pugh b or c), discontinue besremi [see dosage and administration (2.2) and warnings and precautions (5.11)] . - keep your besremi prefilled syringes in their original carton (figure b) while stored. - do not freeze the prefilled syringes. - do not use a prefilled syringe that has been frozen or left in direct sunlight. - keep besremi prefilled syringes, needles, and all medicines out of the reach of children. - your healthcare provider will tell you the prescribed dose that you should take and the right amount of besremi to measure in the prefilled syringe for your dose. each time you inject, be sure that you know the prescribed dose of besremi to inject. your dose may change over time. - besremi is for subcutaneous (under the skin) injection only. - besremi is for one-time use only. do not reuse your prefilled syringe or needle. - do not use a prefilled syringe or needle that is damaged or broken. contact your healthcare provider for a replacement prefilled syringe or additional needles. - inject besremi into the top of the thighs or lower stomach-area just under the skin. do not inject besremi into any other area of the body. - throw away (dispose of) the besremi prefilled syringe with needle attached right away after use, even if there is medicine left in the prefilled syringe. see step 10 in the section " dispose of used prefilled syringes and needles." - lower stomach (abdomen) area, at least 2 inches away from the belly button, - top of thighs. do not inject into skin that is irritated, red, bruised, infected, or scarred. besremi is for subcutaneous (under the skin) injection only. rotate (change) the injection site for each injection. - hold the prefilled syringe at eye level with the needle pointing straight up over a paper towel, sink, or trash can. - check that you can see the dose lines and number markings on the prefilled syringe. - pinch the end of the plunger as shown (figure z). - slowly push up on the plunger to remove liquid medicine until the top edge of the gray stopper lines up with the marking for your prescribed dose (figure z). keep holding straight up as you set the dose. important: if you accidentally remove too much liquid medicine, do not inject. contact your healthcare provider or pharmacist. - put your used prefilled syringes and needles in a fda-cleared sharps disposal container right away after use (figure af). do not throw away (dispose of) loose prefilled syringes and needles in the household trash. - if you do not have a fda-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. - made of a heavy-duty plastic, - can be closed with a tight-fitting, puncture-resistant lid without sharps being able to come out, - upright and stable during use, - leak-resistant, and - properly labeled to warn of hazardous waste inside the container. - when your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. there may be state or local laws about how you should throw away used needles and syringes. for more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the fda's website at: http://www.fda.gov/safesharpsdisposal. - do not dispose of your sharps disposal container in your household trash unless your community guidelines permit this. do not recycle your used sharps disposal container. - always keep the sharps disposal container out of the reach of children.

Philippines - English - FDA (Food And Drug Administration)

schering-plough corporation - pegylated interferon alfa 2b - powder for injection sc - 50mcg

Philippines - English - FDA (Food And Drug Administration)

schering-plough corp - pegylated interferon alfa 2b - powder for injection sc - 120mcg